Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | KNSA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
17.61 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 10.645 - 22.10 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 17.61 | USD |
Kiniksa Pharmaceuticals Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.24B | 70.62M | - | 270.26M | 14.08M | 0.20 | 88.31 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Kiniksa Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KNSA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 16.87 | 18.61 | 16.56 | 17.48 | 453,997 | 0.74 | 4.39% |
1 Month | 19.64 | 19.73 | 16.56 | 17.70 | 374,317 | -2.03 | -10.34% |
3 Months | 18.10 | 22.10 | 16.56 | 19.40 | 377,584 | -0.49 | -2.71% |
6 Months | 15.25 | 22.10 | 14.12 | 18.19 | 431,580 | 2.36 | 15.48% |
1 Year | 11.03 | 22.10 | 10.645 | 17.19 | 434,445 | 6.58 | 59.66% |
3 Years | 16.41 | 22.10 | 7.36 | 14.23 | 392,564 | 1.20 | 7.31% |
5 Years | 15.94 | 33.00 | 5.01 | 15.31 | 354,424 | 1.67 | 10.48% |
Kiniksa Pharmaceuticals Description
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. |